Cancer News and Research

Latest Cancer News and Research

Study solves puzzle behind different types of skin cancer on different body parts

A consistent all-over tan may be impossible to achieve because some body areas are much more resistant to tanning than others, a study has found.Researchers - funded by the Medical Research Council (MRC) - at the University of Edinburgh say the results explain why some holidaymakers find it so hard to achieve an even tan all over their body.

4 Aug 2010

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

What As scientists understand more about a tumor's underlying biology, personalized medicine is emerging as the new patient management paradigm. This year, the American Association for Cancer Research will host its fourth Molecular Diagnostics in Cancer Therapeutic Development: Challenges and Horizons conference at the Sheraton Denver Downtown Hotel in Denver, Colo. This meeting regularly draws representatives from academia and industry to discuss the latest in diagnostic tools and emerging therapies.

4 Aug 2010

Smokers are 11 times more likely to develop subareolar abscess

Women who smoke or pierce their nipples are more likely to develop a breast abscess, according to a new study in the July issue of the Journal of the American College of Surgeons. Researchers at the University of Iowa found the odds of developing primary breast abscess were six times higher in smokers than in nonsmokers, and smokers were 11 times more likely to develop subareolar abscess. Breast abscesses were 15 times more likely to recur in smokers than in nonsmokers. In addition, this study is one of the first to provide clinical evidence that nipple piercing is also a risk factor for subareolar breast abscess, with the onset of abscess occurring from one month to seven years from the time of piercing.

4 Aug 2010

ZymoGenetics second-quarter net loss declines to $3.8 million

ZymoGenetics, Inc. today reported substantially improved financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the company's net loss declined to $3.8 million, or $0.04 per share, a $23.2 million improvement from the $27.0 million loss, or $0.39 per share, reported for the second quarter of 2009. The improvement resulted from higher revenues as well as reduced operating expenses.

4 Aug 2010

BCM collaborates with Roche NimbleGen for high throughput exome capture technology

The Baylor College of Medicine Human Genome Sequencing Center has standardized its target enrichment human disease research studies on Roche NimbleGen Sequence Capture Exome technology. The Baylor HGSC will sequence over 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases and will employ NimbleGen SeqCap EZ Exome and customized NimbleGen exome designs as the exome capture technology of choice. More than 15 different diseases will be investigated by Baylor HGSC, including brain, liver, pancreatic, colon, ovarian and bladder cancers, heart disease, diabetes, autism, and other inherited diseases with the goal of better understanding causative mutations and their impact on these diseases.

4 Aug 2010

Dendreon second-quarter revenue increases to $2.8 million

Dendreon Corporation today reported results for the quarter ended June 30, 2010. Revenue for the quarter ended June 30, 2010 was $2.8 million compared to $25,000 for the quarter ended June 30, 2009. Revenue for the six months ended June 30, 2010 was $2.8 million compared to $55,000 for the six months ended June 30, 2009.

4 Aug 2010

Study to understand processes that lead to onset of testicular germ cell cancer

Scientists have developed a model that will enable them to investigate, for the first time, how human testes develop in baby boys while they are in the womb. Until now it has been impossible to study testicular development during pregnancy in humans and this discovery will enable researchers to understand the processes that can lead to the onset of testicular germ cell cancer (TGCC) in young adult life, and how factors, such as common environmental chemicals, might play a role.

4 Aug 2010

Enzon second-quarter loss from continuing operations reduces to $5.4 million

Enzon Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2010. For the second quarter of 2010, Enzon reported a loss from continuing operations of $5.4 million or $0.09 per diluted share, as compared to a loss of $19.7 million or $0.43 per diluted share for the second quarter of 2009.

4 Aug 2010

Kohl's, American Cancer Society announce new program to fight against breast cancer

As part of Kohl's Department Stores' commitment to fight breast cancer in Wisconsin with nearly $5 million to the American Cancer Society, Kohl's and the American Cancer Society announce new programs and resources available for Wisconsin women to help in their fight against breast cancer. New resources provide services for women fighting breast cancer and for those looking to learn more about preventative breast health.

4 Aug 2010

Long term decline in hemoglobin may announce onset of colorectal cancer

Anemia, a common blood disorder characterized by low hemoglobin levels, has long been associated with those suffering from colorectal cancer. But researchers at Tel Aviv University have discovered that, more than a symptom of active disease, low hemoglobin levels can actually indicate a potential for colon cancer years before it's diagnosed.

4 Aug 2010

Accuray receives Shonin approval to market CyberKnife G4 Robotic Radiosurgery System

Accuray Incorporated, a global leader in the field of radiosurgery, announced today it received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market the CyberKnife G4 Robotic Radiosurgery System to treat tumors non-invasively anywhere in the body, inclusive of head and neck. The System will be marketed in Japan as the "CyberKnife Radiosurgery System."

3 Aug 2010

Curis reports net loss of $2.1 million for second-quarter 2010

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2010.

3 Aug 2010

Celsion reports net loss of $2.6M for second-quarter 2010

Celsion Corporation, a biotechnology drug development company, today announced financial results for the second quarter and six months ended June 30, 2010 and addressed the progression of the clinical trials of ThermoDox, Celsion's heat activated liposomal encapsulation of doxorubicin. ThermoDox is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular carcinoma and in a Phase I/II trial for patients with recurrent chest wall breast cancer.

3 Aug 2010

Vical second-quarter revenues decrease to $2.1 million

Vical Incorporated today reported financial results for the three months and six months ended June 30, 2010. Revenues decreased to $2.1 million for the second quarter of 2010 from $4.0 million for the second quarter of 2009, primarily as a result of a $1.5 million milestone payment in 2009 from Merck & Co., Inc., based on Merck's ongoing Phase 1 clinical-stage development of an investigational cancer vaccine.

3 Aug 2010

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

Researchers at Columbia University have published the dramatic effects of a natural 33-ingredient compound against prostate cancer cell lines. The impressive results are found in the most recent publication of Integrative Cancer Therapies.

3 Aug 2010

Insulin resistance from obesity leads to lower cognitive performance in children: Research

A study by researchers at NYU Langone Medical Center have found that obese adolescents with type 2 diabetes have diminished cognitive performance and subtle abnormalities in the brain as detected by Magnetic Resonance Imaging (MRI). Identification of cognitive impairments as a complication of type 2 diabetes emphasizes the importance of addressing issues of inactivity and obesity, two important risk factors for the development of the disease among the young.

3 Aug 2010

First patient treated in Phase Ib expansion study of CUDC-101

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase Ib expansion study for CUDC-101 in patients with advanced head and neck, gastric, breast and liver cancers.

3 Aug 2010

NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM

Northwest Biotherapeutics, Inc. today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical trials, in which patients with newly diagnosed Glioblastoma multiforme ("GBM"), the most rapid and lethal type of brain cancer, were treated with NWBT's DCVax®-Brain personalized immune therapy.

3 Aug 2010

U.S. clinical trials provide further evidence of importance of storing umbilical cord blood

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that clinical trials ongoing in the U.S. using umbilical cord blood in the treatment of cerebral palsy, high-risk hematologic cancer, injured spinal cords and Type 1 diabetes provide significant further evidence of the importance of storing umbilical cord blood at the time of birth.

3 Aug 2010

Scientists discover factors that reduce breast screening effectiveness

Scientists have found evidence that the reduced effectiveness of breast screening in women in their 40s is mainly due to their tumours being harder to detect, rather than because they grow faster.Previous research has suggested that breast screening is less effective in women in their 40s than in older women.Two reasons have been identified for this - firstly, that younger women tend to have denser breast tissue which makes it harder to detect tumours on a mammogram; and secondly, because younger women's tumours tend to grow more quickly.

3 Aug 2010

Cancer News and Research

Latest Cancer News and Research

Study solves puzzle behind different types of skin cancer on different body parts

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

Smokers are 11 times more likely to develop subareolar abscess

ZymoGenetics second-quarter net loss declines to $3.8 million

BCM collaborates with Roche NimbleGen for high throughput exome capture technology

Dendreon second-quarter revenue increases to $2.8 million

Study to understand processes that lead to onset of testicular germ cell cancer

Enzon second-quarter loss from continuing operations reduces to $5.4 million

Kohl's, American Cancer Society announce new program to fight against breast cancer

Long term decline in hemoglobin may announce onset of colorectal cancer

Accuray receives Shonin approval to market CyberKnife G4 Robotic Radiosurgery System

Curis reports net loss of $2.1 million for second-quarter 2010

Celsion reports net loss of $2.6M for second-quarter 2010

Vical second-quarter revenues decrease to $2.1 million

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

Insulin resistance from obesity leads to lower cognitive performance in children: Research

First patient treated in Phase Ib expansion study of CUDC-101

NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM

U.S. clinical trials provide further evidence of importance of storing umbilical cord blood

Scientists discover factors that reduce breast screening effectiveness

Industry Focus: Cell & Gene Therapy eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Cancer News and Research

Latest Cancer News and Research

Industry Focus: Cell & Gene Therapy eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in